Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer

Breast Care

Volumn 8, Issue 1, 2013, Pages 60-66

  Reinisch, Mattea ^a   Von Minckwitz, Gunter ^a   Harbeck, Nadia ^b   Janni, Wolfgang ^c   Kümmel, Sherko ^b   Kaufmann, Manfred ^d   Elling, Dirk ^e   Nekljudova, Valentina ^a   Loibl, Sibylle ^a,f  

^a GERMAN BREAST GROUP   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e SANA KLINIKUM OFFENBACH   (Germany)

^f Brustzentrum   (Germany)

Author keywords

Breast cancer; Chemotherapy; Elderly; Side effect; Tolerability

Indexed keywords

CAPECITABINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINORELBINE DITARTRATE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE PLUS DOCETAXEL PLUS DOXORUBICIN; CYCLOPHOSPHAMIDE PLUS DOXORUBICIN; CYCLOPHOSPHAMIDE PLUS EPIRUBICIN; EPIRUBICIN PLUS FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PEGFILGRASTIM; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANTIBIOTIC THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GROUPS BY AGE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PATIENT COMPLIANCE; PRIMARY TUMOR; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; VOMITING; ADJUVANT THERAPY; ADULT; ANTIBIOTIC PROPHYLAXIS; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY;

EID: 84875197809     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000346834     Document Type: Article

References (31)

1. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583
2. Albrand G, Terret C: Early breast cancer in the elderly: Assessment and management considerations. Drugs Aging 2008;25:35-45
3. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R: Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012;13:e148-e160
4. Treatment recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), Mamma 2010; www.ago-online.de/de/fuermediziner/leitlinien/ mamma/.
5. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003;21:3580-3587
6. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-1081
7. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-2065
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials: Lancet 2005;365:1687-1717
9. Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kummel S: Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: Analysis of > 4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 2008;10:R77
10. Pal SK, Hurria A: Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010;28:4086-4093
11. Repetto L: Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003;1:18-24
12. Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, Duenne AA, Miles DW: Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO. Eur J Cancer 2011;47:2387-2395
13. Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E, Hudis C, Cohen HJ, Muss HB: Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: Combined analysis of CALGB 9342 and 9840. Ann Oncol 2012;23:632- 638
14. Rack B, Janni W, Harbeck N, Zemzoun I, Strobl B, Klanner E, de Waal J, Schindlbeck C, Kiechle M, Sommer H: Phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement (4 nodes+) - ADEBAR study. Breast 2003;12 Suppl 1:S37
15. Janni W, Harbeck N, Sommer H: Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel is equieffective, but less toxic than FEC120 in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: The German ADEBAR Phase III Study, Poster discussion, Poster no. 604, SABCS 2009
16. von Minckwitz G, Raab G, Caputo A, Schutte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Eidtmann H, Jackisch C, du BA, Kaufmann M: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685
17. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542-551
18. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M: Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-562
19. von Minckwitz G, Kummel S, du BA, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M: Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19:292-298
20. Pentheroudakis G, Fountzilas G, Kalofonos HP, Golfinopoulos V, Aravantinos G, Bafaloukos D, Papakostas P, Pectasides D, Christodoulou C, Syrigos K, Economopoulos T, Pavlidis N: Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol 2008;66:237-247
21. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Pritchard K, O'Brien P, Shepherd LE: Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk nodenegative breast cancer. J Clin Oncol 2010;28:77-82
22. Du XL, Osborne C, Goodwin JS: Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-4642
23. Kummel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Lichtenegger W, Elling D: Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: Feasibility and tolerability in a subset of patients in a randomized trial. Crit Rev Oncol Hematol 2006;58:166-175
24. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 2005;16:56-63
25. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166-5170
26. Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Rodriguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del PP, Ruiz BM, Zaluski J, Arcusa A, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li J, Lopez Garcia-Asenjo JA, Saez A, Rios MJ, Almenar S, Peiro G, Lluch A: Adjuvant docetaxel for highrisk, node-negative breast cancer. N Engl J Med 2010;363:2200-2210
27. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-2313
28. Janni W, Harbeck N, Sommer H: Final toxicity analysis of the ADEBAR phase III study evaluat- ing the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement, Poster no. 3069; 2007
29. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Weber DC, Zielinski C: 2010 update of EORTC guidelines for the use of granulocyte -colony stimulating factor to reducethe incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32
30. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb- Esfahani S, Mehta K, Loibl S: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133-140
31. von Minckwitz G: ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophospamide(C) (or CMF) vs. nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast. Abstracts of ASCO 2010. J Clin Oncol 2010;28(15S):8s (suppl; abstr TPS 104).